Success Metrics

Clinical Success Rate

67.4%

Based on 60 completed trials

Completion Rate

67%(60/89)

Active Trials

61(34%)

Results Posted

80%(48 trials)

Terminated

29(16%)

Phase Distribution

Ph phase_4

Ph not_applicable

Ph phase_2

41%

Ph phase_1

45%

Ph early_phase_1

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution168 total trials

Early Phase 1First-in-human

1(0.6%)

Phase 1Safety & dosage

80(47.6%)

Phase 2Efficacy & side effects

73(43.5%)

Phase 3Large-scale testing

9(5.4%)

Phase 4Post-market surveillance

3(1.8%)

N/ANon-phased studies

2(1.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

58.8%

60 of 102 finished

Non-Completion Rate

41.2%

42 ended early

Currently Active

trials recruiting

Total Trials

177

all time

Status Distribution

Active(65)

Completed(60)

Terminated(42)

Other(10)

Detailed Status

Completed60

Active, not recruiting34

Terminated29

Recruiting27

Withdrawn13

unknown10

Development Timeline

Analytics

Development Status

Total Trials

177

Active

Success Rate

67.4%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (0.6%)

Phase 180 (47.6%)

Phase 273 (43.5%)

Phase 39 (5.4%)

Phase 43 (1.8%)

N/A2 (1.2%)

Trials by Status

recruiting2715%

not_yet_recruiting42%

active_not_recruiting3419%

completed6034%

terminated2916%

unknown106%

withdrawn137%

Recent Activity

61 active trials

Showing 5 of 177

active_not_recruitingphase_2

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

NCT02231775

recruitingnot_applicable

MRD-positive AML Clinical Study

NCT07131059

active_not_recruitingphase_2

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

NCT01979523

recruitingphase_3

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

NCT06475989

active_not_recruitingphase_2

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

NCT02642042

View all 177 trials

Clinical Trials (177)

Showing 20 of 177 trialsScroll for more

NCT02231775Phase 2

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Active Not Recruiting

NCT07131059Not Applicable

MRD-positive AML Clinical Study

Recruiting

NCT01979523Phase 2

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Active Not Recruiting

NCT06475989Phase 3

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Recruiting

NCT02642042Phase 2

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Active Not Recruiting

NCT04111458Phase 1

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Active Not Recruiting

NCT02465060Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active Not Recruiting

NCT07110246Phase 2

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Recruiting

NCT03091257Phase 1

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Active Not Recruiting

NCT03899155Phase 2

Pan Tumor Rollover Study

Recruiting

NCT03065387Phase 1

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Terminated

NCT03190915Phase 2

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Active Not Recruiting

NCT03087071Phase 2

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Active Not Recruiting

NCT03225664Phase 1

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Active Not Recruiting

NCT07468071Phase 1

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Recruiting

NCT03340506Phase 4

Dabrafenib and/or Trametinib Rollover Study

Recruiting

NCT04116541Phase 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Recruiting

NCT03975829Phase 4

Pediatric Long-Term Follow-up and Rollover Study

Active Not Recruiting

NCT03085056Early Phase 1

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer